Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities
Authors:
- Anastasia GaninaAGAnastasia Ganina
- Manarbek AskarovMAManarbek Askarov
- Larissa KozinaLKLarissa Kozina
- Madina KarimovaMKMadina Karimova
- Yerzhan ShayakhmetovYSYerzhan Shayakhmetov
- Perizat MukhamedzhanovaPMPerizat Mukhamedzhanova
- Aigul BrimovaABAigul Brimova
- Daulet BerikbolDBDaulet Berikbol
- Elmira ChuvakovaECElmira Chuvakova
- Lina ZaripovaLZLina Zaripova
- Abay BaigenzhinABAbay Baigenzhin
Open Access
- 6 December 2024
- journal article
- review article
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 92 (6) , 504-525
Abstract
This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy like combined immunotherapy and radiation therapy.Keywords
All Related Versions
Funding Information
- Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (AP19680098)
This publication has 147 references indexed in Scilit:
- Low‐dose radiation therapy mobilizes antitumor immunity: New findings and future perspectivesInternational Journal of Cancer, 2023
- Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the USJAMA Oncology, 2021
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung CancerJAMA Oncology, 2020
- Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanismviarecruitment of myeloid-derived suppressor cellsInternational Journal of Cancer, 2013
- The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu miceCancer Immunology, Immunotherapy, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- An analysis of variability in the manufacturing of dexosomes: Implications for development of an autologous therapyBiotechnology and Bioengineering, 2005
- A Phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinomaCancer, 1997
- Potentiation of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti-(tumor-associated antigen) bispecific antibodyCancer Immunology, Immunotherapy, 1994
- Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancerCancer Immunology, Immunotherapy, 1987